Drug
Bmn 351
Bmn 351: highest development phase Phase 2, developed by BioMarin Pharmaceutical. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- BioMarin Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| BMN 351 NCT07573631 | Phase 2 | Duchenne Muscular Dystrophy (DMD) |
| BMN 351 NCT06280209 | Phase 1/2 | Duchenne Muscular Dystrophy |
Latest
No recent events.
Follow Bmn 351 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.